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Abbreviations (for diseases see Table 2): Ab, antibody; AP, alternative pathway; ASO, antisense 
oligonucleotide; RNAi, ribonucleic acid interference; CP, classical pathway; LP, lectin pathway; FB, 
factor B; FD, factor D; FH, factor H; FI, factor I; MASP, mannose-associated serine protease 1; PNS, 
peripheral nervous system; CNS, central nervous system; MAC, membrane attack complex; FDA, The 
Food and Drug Administration; EMA, European Medicines Agency; SM, small molecule; IV, 
intravenous; SC, subcutaneous; IVT, intravitreal; Ph, phase; RoA, route of administration; SoC, 
standard of care; ULN, upper limit of normal; AQP4, Aquaporin-4. 
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Abstract 
The complement system is well known for its role in innate immunity and in maintenance of tissue 
homeostasis, providing a first line of defence against infection and playing a key role in flagging 
apoptotic cells and debris for disposal. Unfortunately, complement also contributes to pathogenesis 
of many diseases, in some cases driving pathology, and in others amplifying or exacerbating the 
inflammatory and damaging impact of non-complement disease triggers.  The driving role of 
complement in a single disease, paroxysmal nocturnal hemoglobinuria (PNH), provoked the 
development and eventual FDA (US Food and Drug Administration) approval of eculizumab 
(Soliris™), an anti-C5 antibody, for therapy. Although PNH is very rare, eculizumab provided clinical 
validation and demonstrated that inhibiting the complement system was not only well-tolerated, but 
also provided rapid therapy and saved lives. This clinical validation, together with advances in 
genetic analyses that demonstrated strong associations between complement and common 
diseases, drove new drug discovery programmes in both academic laboratories and large 
pharmaceutical companies. Numerous drugs have entered clinical development and several are in 
phase 3 trials; however, many have fallen by the wayside. Despite this high attrition rate, crucial 
lessons have been learnt and hurdles to development have become clear. These insights have driven 
development of next generation anti-complement drugs designed to avoid pitfalls and facilitate 
patient access. In this article, we do not set out to provide a text-heavy review of complement 
therapeutics but instead will simply highlight the targets, modalities and current status of the 
plethora of drugs approved or in clinical development. With such a fast-moving drug development 
landscape, such a compendium will inevitably become out-dated; however, we provide a snapshot 
of the current field and illustrate the increased choice that clinicians might enjoy in the future in 
selecting the best drug for their application, decisions based not only on efficacy but also cost, 
mechanistic target, modality and route of delivery. 
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Complement plays a key role in immune defence and tissue homeostasis 
 
Complement, a key arm of the immune system, is a protein cascade, triggered by specific recognition 
molecules and progressing through a series of protein/protein interactions that culminates in the 
formation of a cytolytic pore (Holers, 2014; Merle et al., 2015). Efficient amplification on pathogens 
ensures an effective response (Harrison, 2018; Lachmann, 2009). Complement proteins are largely 
generated by the liver and are abundant in plasma (up to 5% total protein), although many are also 
produced, sometimes exclusively, at extra-hepatic sites (Morgan and Gasque, 1997). The entire 
cascade progresses from C1 activation through to membrane attack complex (MAC) formation, 
interactions dictated by de novo binding sites revealed following protein conformational changes 
resulting from proteolytic cleavage of the circulating, native protein (C3, C4, C2, FB, C5) or as a 
consequence of unfolding (C9) or protein/protein interaction (C6-C9). 
 
The classical pathway (CP) is initiated when antigen-antibody complexes bind the recognition 
moiety, C1q, triggering activation of the associated proteases, C1r and C1s. Activated C1s cleaves C4 
to C4b which binds covalently through its thioester to the target and there captures C2 which is also 
cleaved by C1s to form the CP C3 convertase C4b2a. The lectin pathway (LP) differs from the CP only 
in the recognition/initiation unit which binds to bacterial sugars, lectins such as mannose binding 
lectin (MBL), ficolins or collectins. All bind carbohydrate epitopes, triggering activation of the 
associated proteases MASP1 and MASP2, the latter cleaving C4 and C2 to form C4b2a (Endo et al., 
2015; Farrar et al., 2016). C4b2a cleaves C3 to C3b, exposing the internal thioester that covalently 
binds C3b to surfaces, causing activating surfaces to become densely coated in C3b (opsonised), 
providing ligands for phagocyte uptake of the target, a crucial defence against infection. C3b also 
associates with the C3 convertase to create the C5 convertase C4b2a3b.  
 
The alternative pathway is initiated by C3b (generated from the activation pathways or non-specific 
sources) binding factor B (FB), which is then cleaved by factor D (FD) to form the C3 convertase, 
C3bBb. C3bBb cleaves C3 to C3b, coating adjacent surfaces and generating a C5 convertase, 
C3bBbC3b. Tickover activation of C3 in the fluid phase primes the system for rapid amplification on 
activating surfaces (Harrison, 2018; Lachmann et al., 2018), typified by absence of the regulatory 
proteins that suppress activation on self cells (Morgan and Meri, 1994). FB can bind to any C3b 
deposited on an activating surface, including that resulting from activation of the classical and lectin 
pathways. Thus, the alternative pathway is known as the amplification loop of the complement 
cascade and plays a crucial role in amplifying any small trigger to a large downstream response.  
4 
 
The terminal pathway begins with the capture and cleavage of C5 by either of the C5 convertases, 
releasing a proinflammatory peptide, C5a. C5b remains attached to the convertase and binds 
sequentially C6 and C7 and, after release of C5b67 from the convertase and association with 
membrane, C8 and C9 bind to form the lytic MAC. Recent studies have illustrated the structural 
complexity of the MAC pore (Hadders et al., 2012; Menny et al., 2018; Serna et al., 2016).  Notably, 
while MAC efficiently lyses aged (or unprotected) erythrocytes and susceptible bacteria, when 
formed on nucleated self-cells it triggers a plethora of activation events, many of which are highly 
pro-inflammatory (Triantafilou et al., 2013).  
 
Complement regulatory proteins include plasma proteins factor H (FH) and C4b-binding protein 
(C4bp) and membrane proteins, CD35, CD46 and CD55 that inhibit the C3/C5 convertases. Control of 
the enzymes is brought about by decay accelerating activity, characterised by binding of control 
proteins, such as FH or CD55, to the multimolecular convertases and rapid dissociation of the 
enzymatic subunit, Bb or C2a. The C3b or C4b that remains is subject to cofactor activity where 
regulatory proteins bind the remaining subunit, enabling a complement serine protease, factor I (FI) 
to cleave and inactivate the substrate forming iC3b/C3dg or C4d/C4c. The MAC inhibitor CD59 blocks 
formation of the lytic pore as soon as C8 is bound to the complex, thus preventing polymerisation of 
C9. Together these control proteins control complement activation on self-tissues (Holers, 2014; 
Merle et al., 2015; Morgan and Meri, 1994).  
 
Complement receptors bind the degradation fragments of C3 and C4, providing an additional route 
for immune defence.  The activation fragments C3a and C5a, bind receptors (C3aR/C5aR1/C5aR2) on 
numerous cell types to trigger diverse responses, ranging from neutrophil recruitment and 
activation, to priming of endothelial cells to enhance adhesion (Coulthard and Woodruff, 2015; 
Wetsel, 1995). C5a/C5aR interactions activate the NLRP3 (NOD-, LRR- and pyrin domain-containing 
3) inflammasome, impact T cell responses in adaptive immunity and play a multitude of other roles 
(Arbore and Kemper, 2016; Triantafilou et al., 2013). The receptors CR3 and CR4 on phagocytic cells 
bind iC3b to promote uptake and clearance of opsonised targets, while C3dg engages CR2 on B cells 
and follicular dendritic cells (FDCs) to amplify the immune response to opsonised antigens (Carroll 
and Isenman, 2012; Dempsey et al., 1996). As a consequence of these interactions, complement is 
intricately entwined in numerous and complex ways with all arms of immunity and host defence 
(Arbore et al., 2017; Kolev et al., 2014). 
 
Understanding roles of complement in disease fuels drug discovery 
5 
 
 
Complement dysregulation occurs when the activation and control mechanisms of complement that 
together play crucial roles in maintaining health and tissue homeostasis fail; when the delicate 
balance between activation and control is disturbed, tissue damage and disease ensue (Ricklin and 
Lambris, 2013; Ricklin et al., 2016; Rodriguez de Cordoba et al., 2012). This dysregulation can be a 
consequence of autoantibodies against regulatory proteins preventing complement control 
(Brocklebank et al., 2017; Goodship et al., 2012; Paixao-Cavalcante et al., 2012), or gene mutations 
or polymorphisms in complement proteins leading to altered expression or function (Harris et al., 
2012; Heurich et al., 2011; Rodriguez de Cordoba et al., 2012). Autoantibodies against tissue 
antigens can also drive inappropriate complement activation and damaged tissue drives further 
activation and dysregulation in a vicious cycle of inflammation and tissue damage.  
 
Complement involvement in disease has been recognised for more than 50 years, particularly in 
diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE) (Schur and 
Austen, 1968) (see Table 1 for all disease abbreviations). Despite this recognition, there was some 
resistance to therapeutic targeting of the system based on concern that blocking a crucial arm of 
innate immunity would be unsafe (Harris, 2018). The demonstration that MAC caused haemolysis in 
the ultra-rare disease paroxysmal nocturnal hemoglobinuria (PNH) broke this resistance and led to 
the development of the blockbuster MAC-blocking anti-C5 drug, eculizumab (Rosse and Dacie, 
1966). Eculizumab, a game-changer therapy, was approved by the  Food and Drug Administration 
(FDA) for treatment of PNH in 2007, some 40 years after the recognition that complement caused 
this devastating disease (Rother et al., 2007). Approval of eculizumab for PNH therapy brought much 
needed clinical validation and demonstrated that blockade of complement could be achieved 
relatively safely and bring about profound and life-changing results. Eculizumab was the first drug to 
be approved that blocked the complement pathway completely at a specific point, the only other 
complement drugs currently approved for therapy have been replacement therapies for C1inh 
(Berinert, Cinryze, Ruconest) in hereditary angioedema (HAE) where C1inh deficiency causes 
dysregulation of the complement and kinin systems (Csuka et al., 2017; Morgan, 2010).  The slow 
progress along the road to approval for anti-complement drugs evidences the complexities of 
successful drug development for inhibition of an abundant and important effector system; many of 
the barriers to progress remain today.  
 
Common complement driven diseases really came to prominence in 2005 when frequent 
polymorphisms in FH were shown to dictate risk for the common blinding disease, age-related 
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macular degeneration (AMD) (Hageman et al., 2005; Haines et al., 2005; Klein et al., 2005). At that 
time, eculizumab was proving successful in clinical trials for PNH and the suggestion that 
complement dysregulation was driving this common blinding disease triggered an explosion of 
interest, with numerous biotechnology and pharmaceutical companies initiating anti-complement 
drug discovery programmes. FDA approval for eculizumab in the rare renal disease atypical 
haemolytic uremic syndrome (aHUS) in 2011 fuelled this frenzy, with a procession of new drugs in 
development and clinical trials over the last few years (Brodsky et al., 2008; Harris et al., 2018; 
Morgan and Harris, 2015; Ricklin et al., 2018). Not surprisingly, the focus for these new drugs has 
remained PNH and aHUS, diseases where complement is the primary driver of disease and in which 
complement inhibition has been validated (Harris et al., 2018). The list of diseases (illustrated in 
Figure 1) has expanded to include AMD and many other pathologies where complement is known to 
play a role. These include generalised myasthenia gravis (gMG) where eculizumab was approved by 
FDA and European regulators in 2017 and Neuromyelitis optica spectrum disorder (NMOSD), which 
was approved by the FDA in June 2019. 
 
The success of eculizumab in the treatment of PNH and aHUS demonstrates that the terminal 
pathway is the driving force that damages and/or activates the target cells in these rare diseases. 
The tissues inappropriately under attack, respectively blood cells, particularly erythrocytes, and 
endothelial cells, are readily accessible to the drug as they are exposed to plasma; thus, it is perhaps 
not surprising that these diseases can be effectively treated using systemic C5 blockade. Many other 
diseases are driven by complement dysregulation, as illustrated in Figure 1. These include the renal 
disease C3 glomerulopathy (C3G), the neurological disease NMOSD, the neuromuscular disease gMG 
and the blinding disease AMD; all are target indications for a growing number of anti-complement 
drugs. The evidence for other diseases is rapidly building and a strong case can be made for anti-
complement therapies in diverse diseases, including iatrogenic and surgery-related conditions. 
Increased levels of complement biomarkers in plasma and disease-relevant fluids, such as synovial 
fluid and cerebrospinal fluid, or complement deposition in tissues, indicate that complement is 
abnormally activated, although whether this is cause or effect of disease may need further 
investigation. Genetic associations with disease, positive readouts from animal models and evidence 
from  clinical studies all combine to support a role of complement in pathogenesis and validate 
specific diseases as targets for therapy (Harris et al., 2018; Ricklin and Lambris, 2013; Ricklin et al., 
2016). 
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Challenges, pitfalls and risks associated with blockade of a key arm of innate immunity accompany 
this growth in the scope of anti-complement therapies (Harris, 2018). For example, opsonisation and 
bacteriolytic activity can be severely compromised, increasing risk of infection (Socie et al., 2019). 
Additionally, for most complement proteins, target concentration is high, necessitating huge doses 
of drug, particularly if an individual is in the acute phase of an illness or injury that further increases 
plasma levels of many complement proteins. Tissue damage may be mediated by locally produced 
complement, rather than systemic complement, meaning that tissue access of the drug is critical. 
These factors, together with the wide normal ranges of target proteins found in the general 
population, mean that complement blockade, and particularly the optimal goal for many diseases of 
modulating complement rather than completely blocking, is challenging. New ways to overcome 
these challenges are emerging with next generation drugs progressing through clinical trials as 
described below. 
 
The aim of this article is neither to review complement and disease nor the drug development 
process; many outstanding recent reviews cover these areas and are cited above. Rather we will 
provide a snapshot of the current status of the field, highlighting those drugs which are in clinical 
development or approved, and next generation approaches bringing forward new complement 
targets, applications, modalities and routes of administration (Table 2). 
 
Next generation drugs 
 
Eculizumab has proven very effective in PNH and aHUS; why then are so many of the new drugs 
entering clinical development also targeting these diseases, often even targeting the same element 
of the complement system? The answer is, of course, that it is a safe bet. Approval of eculizumab 
was a major milestone for the field, providing long-sought clinical validation for complement 
inhibition in man. There are, however, drawbacks associated with this drug, including high cost, risk 
of meningococcal infection, frequency and amount of dosing, route of administration and difficult 
pharmacokinetics as the target C5 can increase in concentration under conditions of acute phase, 
resulting in break-through symptoms. There are also clinical issues with the use of eculizumab; 
indeed, in PNH, while major life-threatening complications, such as thrombotic events, are well-
treated, a substantial proportion of patients remain transfusion-dependent on eculizumab (Hillmen 
et al., 2013). PNH erythrocytes lack CD55 (decay accelerator) as well as CD59 (MAC blocker), 
therefore complement continues to amplify. As the cells are no longer removed from the circulation 
by MAC mediated lysis, they accumulate activated C3 on their surfaces and are subject to haemolysis 
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due to phagocytic uptake in the extravascular space (Risitano et al., 2009). Problems such as these, 
together with the ambition to expand the number of indications treated with anti-complement 
drugs, have driven the development landscape illustrated in Table 3 and Figure 2. Novel and 
innovative ways of inhibiting complement that move beyond C5 and ultra-rare diseases and 
circumvent the challenges associated with complement inhibition are evolving; these second 
generation high-potential drugs are rapidly progressing through phase 2 clinical trials and are likely 
to challenge eculizumab and change the field in the near future (Figure 3). Both drugs targeting C5 
(in ways that differentiate from eculizumab) and therapeutics targeting other components and 
pathways of complement are progressing through clinical development. Indeed, a next-generation 
re li g  for  of e ulizu a , ter ed ra ulizu a  Ulto iris™  (Sheridan et al., 2018), has been 
FDA- and EMA-approved for PNH, is under fast-track review for aHUS and is competing phase 3 trials 
in gMG; however, no other new drugs have yet made it past phase 3. 
 
Innovations in next generation drugs are wide and varied. ‘e li g or pH-s it hed  a ti odies a  
be generated from existing antibodies by modifying the antigen-binding region, frequently by 
incorporating histidine residues, such that the antibody while retaining high affinity for target at pH 
7.4,  loses affinity in the acidic pH 6.0 environment of the endosome (below the isoelectric point of 
histidine). When antibody is passively internalised into endothelial cells, the pH drop in the 
endosome results i  dise gage e t of the target a d re li g of the e pt  antibody back to the 
circulation (Igawa et al., 2010). This process improves the pharmacokinetic properties of the drug, 
enabling less frequent dosing. Ravulizumab, the e t ge eratio  re li g  form of eculizumab, is 
administered in PNH every 8 weeks, rather than every 2 weeks, although the dose is much higher 
(3.3 g IV contrasting to 0.9 g IV for eculizumab), a negligible saving on overall drug dose! Another 
recycling anti-C5 antibody is currently in phase 2 development, crovalimab (Roche; SKY59); this 
antibody was selected during the original screening process for its recycling or pH-switched 
properties (Fukuzawa et al., 2017; Sampei et al., 2018). Crovalimab is being developed as a SC-
administered agent and dosing schedules in reported trials suggest that a lower dose (340 mg every 
two weeks) was effective (Risitano et al., 2019). Crovalimab is also effective in patients carrying the 
R885H C5 variant (common in Japan), resistant to eculizumab inhibition. A different approach to 
decrease drug dose is to develop an agent that binds neoepitopes on complement proteins rather 
than targeting the native protein. Various drugs are in clinical development, including IFX-1 (InflaRx), 
which binds the released C5a fragment (Riedemann et al., 2017), and the preclinical antibody, 
BIVV020 (Sanofi), reported as binding activated C1s.  
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Route of administration is a critical consideration. The move from IV administration to SC or even 
oral administration has been rapidly progressing. As well as crovalimab, noted above, several 
peptide-based anti-complement drugs are being administered SC, including APL-2 (C3 inhibitor; 
Apellis), AMY101 (C3 inhibitor; Amyndas) and zilucoplan (C5 inhibitor; RaPharma). Some small 
biologics, such as nomacopan (C5 inhibitor; Akari), are also administered SC, and various strategic 
partnerships announced in company press releases in recent times (for example, Zealand Pharma 
and Alexion) reveal an expanding pipeline of SC drugs. Avacopan (Chemocentryx), an orally active 
inhibitor of C5aR1, is in phase 3 for antineutrophil cytoplasmic antibodies (ANCA)-associated 
vasculitis (AAV) and in phase 2 for a number of other indications (Table 3) (Bekker et al., 2016). 
Other orally bioavailable drugs are progressing through phase 2 with a focus on the amplification 
loop. LNP023 (Novartis) blocks FB and is in clinical trials (oral route twice daily) for a number of 
indications including PNH and renal disease (Schubart et al., 2019). A hillio s “M FD i hi itors are 
also being tested in these indications, although the target has a very high synthesis rate (1.33 
mg/kg/day) (Pascual et al., 1988), necessitating thrice daily oral administration. Other oral drugs are 
in preclinical development, including RaPhar a s SM targeting C5. Such orally-bioavailable SM 
drugs, including targets within the amplification loop and C5, are likely to change the landscape of 
complement drug development in the years to come. While the required dosing may be frequent, 
due to target concentration or turnover, the oral route and ability to rapidly reverse inhibition by 
stopping treatment in the face of infection or other complication may be of huge benefit. 
Targeting at the nucleotide level offers a different approach to overcome the challenge of high 
target concentration and drug dose, the goal is to prevent translation of the protein and thus its 
release to the blood stream. Alnylam and Ionis have led the way with, respectively, C5 RNAi 
(ribonucleic acid interference; cemdisiran) and FB antisense oligonucleotide (ASO), both in phase 2, 
the former for IgA nephropathy (IgAN) and the latter for AMD (Grossman et al., 2017; Kusner et al., 
2019). Cemdisiran was originally trialled in PNH and although it successfully blocked synthesis of C5 
to 98% the trace residual C5, possibly generated extra-hepatically, resulted in some lysis with lactate 
dehydrogenase (LDH) ~ 1.5 times upper limit of normal (ULN; press release December 5th 2016). 
Generation of complement components by tissues outside of the liver, such as FD by adipocytes, C7, 
C1q and properdin by cells of monocytic lineage, can limit utility of this liver-targeting approach. 
Many tissues, including the central nervous system (CNS) and the joint can generate all components 
of the complement cascade, particularly when cells are under the influence of inflammatory 
cytokines. Even when the liver contributes the majority of a specific protein, local biosynthesis may 
be the driver of disease or pathology, for example in kidney transplant (Farrar et al., 2006; Pratt et 
al., 2002); this may stymie anti-sense approaches targeting hepatic synthesis.  
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Local and targeted  inhibition of complement has been the driver behind a number of innovative 
drugs which deliver therapy to tissues; various targeting moieties have been reported, some of 
which bind C3 fragments and others that bind epitopes exposed on damaged tissues (Holers et al., 
2013; Holers et al., 2016; Ruseva et al., 2015). TT30, initially developed by Taligen Therapeutics and 
taken through phase 1 testing by Alexion in PNH (Fridkis-Hareli et al., 2011), is a chimeric molecule, 
with one arm binding complement activation fragments in tissues, and the second arm comprising 
the complement regulator domain, here the amino-terminal portion of FH. This agent homes to the 
tissue under attack, delivering lasting therapy, while excess agent is excreted or metabolised. Such 
agents have several advantages, not only should they decrease dose of drug as they target activated 
complement, not native proteins, but they should also lower risk of infection as systemic inhibition is 
transient. TT30 has not progressed beyond phase 1 but various similar agents remain in preclinical 
development. A number of companies have reported development of gene therapy-based agents for 
treatment of AMD (for example, Gyroscope Therapeutics https://gyroscopetx.com/; Gemini 
Therapeutics https://www.geminitherapeutics.com/), with exciting potential for local therapy, but 
the nature of these drugs and their targets are not disclosed.  
 
Crossing barriers presents a particular problem for CNS diseases; to date, none of the drugs in 
development has been selected for capacity to cross the blood-brain barrier (BBB) and access the 
CNS; given that complement has been implicated in a number of CNS disorders, this is a major 
unmet need (Carpanini et al., 2019). It is possible, although difficult, expensive and risky, to inject or 
infuse drugs directly into the intraventricular or intrathecal space. Thus, a number of approaches for 
rossi g the BBB are i  de elop e t; these i lude the troja  horse  ethod of pigg -backing drugs 
onto peptides or antibodies that target receptors, such as the transferrin receptor or insulin 
receptor. These delivery methods are reviewed extensively elsewhere (Abdul Razzak et al., 2019; 
Carpanini et al., 2019). Although not a complement target, gene therapy targeting motor neurons 
was approved by the FDA in 2019 for treatment of spinal muscular atrophy in children (Zolgensma™) 
illustrating the potential for gene therapy in the CNS. This drug utilises a non-replicating adeno-
associated virus (AAV9) vector that can cross the BBB to deliver the target gene. In a recent press 
release (July 18, 2019), Apellis announced the development of APL-9, a PEGylated C3-inhibiting 
peptide designed to prevent rapid complement-mediated attack on AAV-based vectors and improve 
efficacy of gene therapy. 
 
Selecting and stratifying diseases and individual patients for complement interventions will be 
challenging as the field expands beyond the ultra-rare complement-driven conditions.  First, it will be 
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necessary to demonstrate that complement activation is occurring in the candidate disease; second 
it is important to consider heterogeneity – that some patients with a particular disease label may 
have a highly complement driven disease while others will not; interventions can only work in the 
former group. As an example, multiple sclerosis, although typified by CNS myelin loss and resultant 
functional deficits, encompasses a spectrum of disease types; pathological studies have shown that 
complement deposits in brain are a major feature in about a third of cases (Lucchinetti et al., 2000). 
Similarly, with the focus of anti-complement therapy in renal disease, attention has focussed in 
recent years on treatment of the devastating renal disease, C3G, for which there is no FDA-approved 
therapy. Unlike in aHUS, it is thought that C3 dysregulation dominates in the fluid phase in C3G, with 
dysregulation of surface-bound C5 convertase in a subset of patients. Case reports, and a small 
clinical trial in the US (six patients) using eculizumab to treat C3G, describe some improvement in a 
subset of patients (Lebreton et al., 2017; Nester and Smith, 2016).  Limited data on a heterogeneous 
disease make therapeutic evaluation difficult, but improvement in renal function may correlate with 
high plasma terminal complement complex (TCC) levels pre-treatment and evidence of rapidly 
progressive or acute crescentic disease (Le Quintrec et al., 2015). Recent guidance from NHS England 
supports use of eculizumab in a tightly stratified group of post-transplant patients with evidence of 
acute inflammation and disease recurrence on kidney biopsy. Stratification and selection will be 
particularly important for clinical trials, including only those patients with evidence of complement 
dysregulation. Stratification can be based on complement activation biomarkers, particularly 
activation fragments and complexes, in plasma or other biological fluids, as recently described for 
predi ti g progressio  i  Alzhei er s disease  (Hakobyan et al., 2016). 
 
How much inhibition is enough is an important and unanswered question that will need to be 
addressed as complement therapeutics become more widely used. In this context, PNH, the first 
disease target, is unique in that complete inhibition of MAC formation is essential; PNH erythrocytes 
are devoid of complement regulators and even a small amount of free C5 in eculizumab treated 
patients is sufficient to cause breakthrough haemolysis (Kelly et al., 2008). In most other disease 
situations, turning down rather than turning off complement is likely to be sufficient to confer 
therapeutic effect. The aim of treatment would be to reverse dysregulation and restore 
homeostasis. In this context, the amplification loop represents an excellent target. Reducing cycling 
through the amplification loop by increasing loop regulation or reducing availability of convertase 
could enable fine-tuning of therapy to ameliorate pathology while retaining the protective roles of 
complement in immune defence. This will be a significant advantage for treating common diseases 
in elderly and infection-vulnerable individuals in the community. Several AP-specific drugs are in 
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phase 2 development, including inhibitors of FB and FD. Other drugs which have modulatory 
properties are on the horizon; homing agents described above which deliver functional domains of 
regulators such as FH can directly modulate the convertase enzymes, as can the preclinical molecule 
AMY201 (Amyndas), a truncated, recombinant form of FH engineered to bind with superior efficacy 
to target surfaces. Gene therapies designed to boost the tissue s a ilit  to o trol o ple e t at 
disease sites have exciting potential to modulate. Finally, it may be possible to block natural 
modifiers of complement; properdin stabilises the AP convertase enzymes and MASP3 activates FD, 
interference at these levels using drugs such as CLG561 (anti-properdin, Novartis) or OMS906 
(preclinical anti-MASP3, Omeros) may nudge the complement system towards restored 
homeostasis. Importantly, anti-properdin in animal models can have beneficial or detrimental 
effects depending on the disease, highlighting the absolute requirement for full understanding of 
disease mechanism and appropriate patient stratification in order to get the right drug into the right 
patient at the right time (Ruseva et al., 2012; Ueda et al., 2018). 
 
Concluding remarks 
This article has sought to provide a snapshot of the anti-complement drug landscape at the time of 
writing.  The landscape is complex and fast moving, so inevitably, there will be changes even by the 
time that this is published.  Nevertheless, we suggest that the Compendium captures the 
complexities and direction of travel of the field and illustrates the trends and assumptions that have 
shaped the field to date. 
 
In the twelve years since the approval of eculizumab for PNH, overnight transforming complement 
inhibition from an archaic interest in animal models to a clinically tractable target in human disease, 
there has been considerable activity, with many companies, large and small, launching complement 
programmes and complement-targeted drugs; however, progress to clinical use has been 
disappointing.  Apart from eculizumab, its successor ravulizumab and various takes on the venerable 
C1inh, nothing new has been approved, although intense activity in clinical trial phases 2 and 3 
predicts rapid change in the clinical tool o  i  the ear future.  The re e t e te sio  of Ale io s ke  
patents in the US for eculizumab through to 2027 (press release August 15th 2017) may inhibit 
challengers in the C5 mAb space but other approaches to complement inhibition may, perversely, be 
prioritised and accelerated.  
 
Looking back, the view is more battlefield than landscape, littered with the corpses of abandoned or 
failed drugs.  In part, this carnage is a result of an over- o ser ati e e too  approa h that has 
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focussed on the very areas in which eculizumab has been successful – targeting C5 in PNH and other 
ultra-rare diseases; many of the survivors have sought to diversify in terms of complement targets 
and, to some extent, disease targets. Nevertheless, most remain focussed on ultra-rare or rare 
diseases. The exception to date has been AMD, a relatively common disease where the genetics 
made the case for testing anti-complement drugs. Although local (intravitreal) therapies have 
predominated to date, systemic approaches are also being explored; these may lay the foundations 
for anti-complement drugs in other common and chronic complement dysregulation diseases where 
there is considerable unmet need.   
 
Looking forward, there is every reason to be optimistic.  There is intense activity, many new Pharma 
entrants to the area, a broadening of disease focus and a growing enthusiasm to move beyond C5 
with some innovative approaches that may reduce costs and address safety issues. Belatedly, the 
field has realised that for most complement dysregulation diseases – perhaps all except PNH – the 
aim should be to reduce not eliminate complement activation in order to restore homeostasis. This 
should be low risk, particularly with regard to bacterial infections, and may open the door to orally 
active agents that will revolutionise the field.  Our expectation is for continued rapid progress and a 
landscape that will, in just a few years, have changed beyond recognition.        
 
 
Figure Legends 
 
Figure 1. Complement activation is implicated in numerous diseases. Complement exists in a 
delicate balance between activation and regulation. When that balance becomes disturbed, tissue 
can be damaged and disease ensues. Complement is implicated in many different diseases although 
in many cases it acts to exacerbate a cycle of inflammation induced by other triggers or causes; anti-
complement therapy may have a role to play in treatment of these diseases. In some cases, such as 
PNH, aHGUS and C3G, complement is the main driver of disease. These diseases are more prevalent 
in clinical trial and are  are indicated in red in the figure. Anti-complement therapy is thought to play 
a key role in the treatment of these diseases. Refer to Table 1 for all disease abbreviations. Cartoons 
from PRESENTERMEDIA (www.presentermedia.com). 
 
Figure 2. Anti-complement drugs currently in clinical development. The concentric rings indicate 
the different phases of clinical develop e t, ith appro ed  i  the e tre. O l  drugs urre tl  i  
clinical development are shown and the most advanced stage of development for any indication is 
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shown; trials posted but not yet recruiting are included. Colouring and shape indicate modality and 
route of administration. There are a number of drugs in clinical development, indicated as preclinical 
or first-time-in-human on company websites (Gyroscope Therapeutics, Gemini Therapeutics and 
others), these are only included in this diagram if targets have been disclosed. The inclusion of C1inh 
drugs in this figure reflects their repurposing for complement-mediated complications of kidney 
transplant. 
 
Figure 3. Development of next generation drugs.  
The pyramid indicates the potential path of tra el for e t ge eratio  a ti-complement drugs. Early 
drugs have been dosed at high levels, often intravenously, with the aim to totally block the pathway. 
Later drugs have longer duration of action and/or can be administered subcutaneously or orally. 
Some drugs in, or approaching, clinical development may have the capacity to modulate the system 
rather than turn it off altogether. The potential to localise therapy to the tissue in need using gene 
therap  or ho i g  age ts presents exciting possibilities. Towards the pinnacle of the pyramid lie 
future drugs, currenty speculation; drugs which can cross the blood brain barrier (BBB) or other 
obstacles, that can reverse dysregulationand restore homeostasis, or that can modulate disease 
outcome by impacting other arms of the immune system or other biological cascades. Cartoons from 
PRESENTERMEDIA (www.presentermedia.com) 
 
 
Table 1. Abbreviations used for diseases in text, tables and figures. 
 
Table 2. Compendium of drugs in development 2019. (a) This table lists all anti-complement drugs 
in clinical development (to the best of our knowledge). For current stage of development for 
different indications please refer to table 3. C1inh drugs (Cinryze, Berinert, Ruconest) have 
previously been reported for HAE, their inclusion in this table reflects their repurposing for 
complement-mediated complications of kidney transplant. Unless otherwise indicated the drug 
lo ks the fu tio  of the target; other ki ds of a ti it  are oted u der additio al i for atio . (b) 
Drugs in preclinical development, only drugs where the target has been disclosed are included. 
Route of administration is not included for preclinical assets. For disease abbreviations refer to Table 
1. IV, intravenous; SC, subcutaneous; IVT, intravitreal, Ab, antibody; RNAi, ribonucleic acid 
interference; ASO, antisense oligonucleotide; SM, small molecule; ULN, upper limit of normal; AQP4, 
Aquaporin-4. 
 
15 
 
Table 3. Drugs in current clinical trial. Each line represents an ongoing clinical and these are shaded 
according to the phase of development. Only company-sponsored trials are indicated and completed 
trials are excluded. Red text indicates that a drug has already been approved for treatment of a 
different indication and is being trialled for a new purpose. For disease abbreviations refer to Table 
1. For modality and route of administration please refer to Table 2. HV; healthy volunteer. 
* Recently approved by FDA for NMOSD, June 2019 
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Table 1. Abbreviations used for diseases in text, tables and figures. 
Abbreviation Disease 
AAV Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis 
AD Alzhei er s disease 
aHUS Atypical hemolytic uremic syndrome 
AKI Acute kidney injury 
AMD Age-related macular degeneration 
AMR Antibody-mediated rejection 
APS Antiphospholipid syndrome 
ARDS Acute respiratory distress syndrome 
BD Berger s disease 
BP Bullous pemphigoid 
C3G C3 glomerulopathy 
C3GN C3 glomerulonephritis 
CAD Cold agglutinin disease 
COPD Chronic obstructive pulmonary disease 
CPB Cardiopulmonary bypass 
DDD Dense deposit disease 
DGF Delayed graft function 
GA Geographic atrophy 
GBS Guillain-Barré syndrome 
gMG Generalized myasthenia gravis 
GPA Granulomatosis with polyangiitis 
GVHD Graft versus host disease 
HAE Hereditary angioedema 
HS Hidradenitis suppurativa  
HSCT-TMA 
Hematopoietic stem cell transplant-related thrombotic 
microangiopathy 
IgAN IgA nephropathy 
I/R Ischemia/reperfusion 
IC-MPGN Immune complex-mediated membranoproliferative glomerulonephritis 
IMNM Immune Mediated Necrotizing Myopathy 
IPCV Idiopathic polypoidal choroidal vasculopathy 
KT Kidney transplant 
LN Lupus nephritis 
MN Membranous nephropathy 
MPA Microscopic polyangiitis 
MS Multiple sclerosis 
NMO (NMOSD) Neuromyelitis optica (spectrum disorder) 
PG Pyoderma Gangrenosum 
PNH Paroxysmal nocturnal hemoglobinuria 
RA/OA Rheumatoid arthritis/Osteoarthritis 
SIRS Systemic inflammatory response syndrome 
SLE Systemic lupus erythematosus 
STGD1 Stargardt Disease 1 
SVS, SS Severe sepsis, septic shock 
TMA Thrombotic microangiopathy 
wAIHA Warm type autoimmune hemolytic anemia 
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wAMD Wet AMD 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
Abbreviations (for diseases see Table 2): Ab, antibody; AP, alternative pathway; ASO, antisense oligonucleotide; RNAi, ribonucleic acid interference; CP, 
classical pathway; LP, lectin pathway; FB, factor B; FD, factor D; FH, factor H; FI, factor I; MASP, mannose-associated serine protease 1; PNS, peripheral 
nervous system; CNS, central nervous system; MAC, membrane attack complex; FDA, The Food and Drug Administration; EMA, European Medicines 
Agency; SM, small molecule; IV, intravenous; SC, subcutaneous; IVT, intravitreal; Ph, phase; RoA, route of administration; SoC, standard of care; ULN, upper 
limit of normal; AQP4, Aquaporin-4. 
 
Table 2. Compendium of drugs in development 2019 
(a) This table lists all anti-complement drugs in clinical development (to the best of our knowledge). For stage of development for different indications 
please refer to table 3. C1inh drugs (Conryze, Berinert, Ruconest) have previously been reported for HAE, their inclusion in this table reflects their 
repurposing for complement-mediated complications of kidney transplant. Unless otherwise indicated the drug blocks the function of the target; other 
ki ds of a ti it  are oted u der additio al i for atio . For disease a re iatio s refer to Ta le . IV, i tra e ous; SC, subcutaneous; IVT, intravitreal, Ab, 
antibody; RNAi, ribonucleic acid,interference; ASO, antisense oligonucleotide; SM, small molecule; ; ULN, upper limit of normal; AQP4, Aquaporin-4. 
 
DRUGS IN CLINICAL DEVELOPMENT OR APPROVED 
Drug name Alternative 
names 
Company Target Modality Route of 
administration 
Additional information 
CLASSICAL PATHWAY 
Cinryze   Takeda 
Pharmaceuticals 
(Originator Shire, 
Takeda 2019) 
C1r/s; MASPs Purified 
native 
protein 
IV; Ph3 trials for SC 
dosing completed 
(NCT02316353, 
NCT02584959) 
Plasma derived protein; controls both 
complement and contact systems.  
Physiological inhibitor of lectin and 
classical pathways, prevents activation 
of C1r/s and the MASPs. 
Originally approved for HAE, now in trial 
for complications of kidney transplant. 
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Berinert  CSL Behring C1r/s; MASPs Purified 
native 
protein 
IV As above. 
 
Ruconest  Pharming C1r/s; MASPs Biologic IV Recombinant C1inh, produced in 
transgenic rabbits (milk). 
Originally approved for HAE, now in trial 
for complications of kidney transplant. 
Sutimlimab  TNT009 
BIVV009 
Sanofi  
(Originator True 
North; Bioverativ 
2017; Sanofi 2018) 
 
C1s Ab IV Showed improvement in haemolytic 
events in CAD (Ph1b). 
LECTIN PATHWAY 
Narsoplimab OMS721 
 
Omeros MASP2 Ab IV; IV loading, daily 
SC maintenance in 
trial (NCT03205995) 
Ph2 in IgAN reports improved 
proteinuria in patients with and without 
concomitant steroid therapy. Those on 
steroids at time of enrolment were able 
to reduce or stop steroids.  
Breakthrough therapy designation 
granted by FDA for IgAN and for high-
risk HSCT-TMA. 
ALTERNATIVE PATHWAY/AMPLIFICATION LOOP/COMPLEMENT C3 
Danicopan ACH-0144471  
ACH-4471 
Achillion FD SM Oral Ph2 data from combination trial with 
eculizumab (in patients with 
transfusion-dependent anemia) 
demonstrated potential to improve 
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anemia and decrease transfusions 
(press release May 17, 2019). 
Enrolment milestone reached in Ph2 
C3G (April 2019), 6 month (blinded) and 
12 month (open label). 
Ph2 proof-of-mechanism in C3G 
reported positive biomarker data (C3 & 
Bb levels) and improved renal function 
(November, 2017).  
ACH-5228  Achillion FD SM Oral ‘eported as e t ge eratio  drug ith 
improved potency and pharmacokinetic 
properties allowing for reduced 
frequency of dosing. 
Ph1 data indicate 120 mg twice daily 
supressed activity of the AP >95% (press 
release July 22, 2019). 
ACH-5448  Achillion FD SM Oral ‘eported as e t ge eratio  drug ith 
improved potency and pharmacokinetic 
properties allowing for reduced 
frequency of dosing. 
IONIS-FB-LRX  Ionis Pharma 
(Partnership with 
Roche) 
 
FB ASO SC LICA technology; blocks (liver) 
expression of FB. 
Ph1 reported dose-dependent 
reductions in FB and a positive safety 
and tolerability profile. 
CLG561 NOV-7 
 
Novartis 
(Morphosys Ab; 
originator Alcon 
Novartis spun off 
Properdin Ab IVT Ph2 in GA, combination with 
Tesidolumab. Data demonstrated no 
significant impact on change in GA 
lesion size. 
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Alcon 2019) 
LPN023  Novartis FB SM Oral Binds the active site of FB and thus 
inhibits the convertase and C3 cleavage. 
APL-2 Pegcetacoplan 
(Derivative of 
compstatin) 
 
Apellis  
(Original molecule 
(POT-4), Potentia 
Pharmaceuticals; 
Alcon 2009; Apellis 
2010) 
C3 Peptide SC other than GA 
which is IVT 
POT-4 (APL-1) is a derivative of 
compstatin; APL-2 is a PEGylated 
derivative. 
Ph3, head-to-head with eculizumab 
completed enrolment.  
Ph2 in PNH reported normalization of 
markers of intravascular and 
extravascular hemolysis.  
Patients in Ph2 CAD/wAIHA showed 
improvement in hematologic measures 
and in quality of life scores, particularly 
in CAD. 
APL-9  Apellis C3 Peptide IV Cyclic peptide with same target and 
mode of action as APL-2; smaller mass 
and shorter half-life.  
Developed to inhibit host response to 
AAV vectors in gene therapy.  
AMY-101 Cp40; 
Derivative of 
compstatin 
 
Amyndas C3 Peptide  SC; IV; administered 
weekly to 
interproximal papilla 
in Ph2 trial for 
gingivitis. 
Compstatin derivative with much 
improved potency compared to original 
molecule (Qu et al., 2013). 
In Ph1, administered SC every 48 hours 
and maintained effective C3 blockade 
with a satisfactory safety profile. 
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Mirococept 
 
APT070 
 
Ki g s College 
London, MRC 
Functional 
domains of 
CR1 targeted 
to 
endothelium 
ia lipid tail  
Biologic Perfused through the 
kidney prior to 
transplant. 
EMPIRIKAL trial. 
Inhibits both CP and AP C3 convertase. 
Based on a natural convertase 
regulator, comprises a fragment of CR1 
and possesses decay and cofactor 
activity (Mossakowska et al., 1999; 
Smith, 2002). 
COMPLEMENT C5 
Eculizumab Soliris 
 
Alexion C5 Ab IV Approved for PNH, aHUS.  
Approved gMG (FDA, October 2017; 
EMA August 2017).  
Approved by FDA for NMOSD (anti-
AQP4+ve), June 2019. 
Tesidolumab LFG316 
NOV-4 
Novartis 
(Morphosys Ab; 
originator Alcon) 
C5 Ab IV 
IVT 
In GA, LFG316 did not reduce lesion 
growth or improve visual acuity. 
Pozelimab 
 
REGN3918 Regeneron  C5 Ab IV & SC Regeneron and Alnylam are 
collaborating with combination therapy 
Pozelimab/Cemdisiran.   
Ph1 HV completed 2018.  
Ph1 in PNH reported on company 
pages. 
Crovalimab RG6107 
RO7112689 
SKY59 
Roche  
(Originator Chugai 
Pharmaceuticals) 
C5 Ab 
(recycling) 
IV and SC 
formulations tested 
‘e li g pH s it hed  a ti od  
leading to reduced dosing (340 mg SC 
every 2 weeks appears effective) 
(Risitano et al., 2019). 
Effective in patients carrying the  R885H 
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C5 variant. 
 
Ravulizumab ALXN 1210 
ULTOMIRIS 
Alexion C5 Ab 
(recycling) 
IV ‘e li g or pH s it hed  a ti od  
leading to reduced dosing. Ultomiris 
administered IV every 8 weeks, Soliris is 
administered IV every 2 weeks. 
Approved for use in adult PNH by FDA 
(December 2018) and EMA (July 2019).  
Supplemental biologics license 
application (sBLA) under priority review 
for treatment of aHUS (June 2019). 
Ph3 trial of SC formulation expected. 
ABP 959  Amgen C5 Ab 
(Biosimilar) 
IV Eculziumab biosimilar; note eculizumab 
patent extension to 2027 (Alexion press 
release August 15th, 2017). 
Zilucoplan RA101495 RaPharma C5 Peptide  SC Positive date reported from Ph2 in gMG 
(December, 2018) and Ph2 in PNH 
(February, 2018). 
 
Zimura ARC 1905  IVERIC bio 
(Changed name 
from Ophthotech 
Corp to IVERIC bio 
in April 2019 as 
transitioned to gene 
therapy company) 
C5 Aptamer IVT Ph2 combination with Lucentis proved 
to be safe but is not being developed 
further (press release, Nov 2018). 
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Nomacopan rVA576 
Coversin 
Akari C5 Biologic SC 
Topical (in AK) 
Recombinant form of tick protein OmCI 
(Ornithodoros moubata complement 
inhibitor). 
Also inhibits leukotriene pathway 
(LTB4). 
Effective in patients carrying the R885H 
C5 variant. 
Ph2 in PNH achieved primary endpoint, 
defined as a reduction i  LDH to ≤ .8 
times ULN. 
Ph2 aHUS reported to be on hold in 
expectation of Q4 2019 trial in pediatric 
HSCT-TMA. 
Early safety and efficacy data in AKC 
Ph1 (topical) were positive (June 19, 
2019). 
Initial Ph2 data in BP demonstrated 
clinical efficacy (3 patients reported). 
Cemdisiran ALN-CC5 Alnylam C5 RNAi SC Blocks (liver) expression of C5. Originally 
tested in PNH; despite effective 
reduction in circulating C5 levels, some 
circulating C5 was detectable and LDH 
levels were ~1.5 times ULN. 
COMPLEMENT C5a/C5aR1 
Avacopan CCX168 Chemocentryx 
(Vifor Pharma has 
rights to 
C5aR1 SM Oral In Ph2 for AAV, avacopan provided 
effective control of the disease while 
allowing elimination of high-dose 
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commercialize in 
Asia, including 
Japan and the 
Middle-East) 
steroids. 
Ph2 in IgAN completed, improved 
proteinuria reported at 12 weeks. 
IFX-1  InflaRx C5a Ab IV Binds C5a but not the native C5 protein. 
 Development in SIRS and sepsis on 
hold. 
Ph2 SHINE study in HS did not meet 
primary endpoint although post-hoc 
data analysis suggested robust anti-
inflammatory activity; development 
continues (press release July 18th 2019). 
MAC (C6-C9) 
AAVCAGsCD
59 
HMR59 Hemera Biosciences Expression of 
soluble CD59 
Gene 
therapy 
IVT Gene therapy, expression of soluble 
CD59 in the retina. CD59 is a natural 
regulator of MAC formation. 
  
 
 
 
Abbreviations (for diseases see Table 2): Ab, antibody; AP, alternative pathway; ASO, antisense 
oligonucleotide; RNAi, ribonucleic acid interference; CP, classical pathway; LP, lectin pathway; FB, 
factor B; FD, factor D; FH, factor H; FI, factor I; MASP, mannose-associated serine protease 1; PNS, 
peripheral nervous system; CNS, central nervous system; MAC, membrane attack complex; FDA, The 
Food and Drug Administration; EMA, European Medicines Agency; SM, small molecule; IV, 
intravenous; SC, subcutaneous; IVT, intravitreal; Ph, phase; RoA, route of administration; SoC, 
standard of care; ULN, upper limit of normal; AQP4, Aquaporin-4. 
 
Table 2 (b) Drugs in preclinical development, only drugs where the target has been disclosed are 
included. Route of administration is not included for preclinical assets. 
 
 
DRUGS IN PRECLINICAL DEVELOPMENT 
Drug name Company Target Modality 
Name not disclosed  RaPharma FD Peptide 
OMS906 Omeros MASP3 Ab 
BIVV020 Sanofi activated C1s Ab 
Name not disclosed RaPharma C1s Peptide 
AMY- , i i-
fa tor H  Amyndas 
Contains functional domains 
of FH; complement modulator 
Biologic 
PRO-02 Prothix BV C2 Ab 
IFX2 InFlaRx C5a Ab 
SOBI005 SOBI C5 Affibody 
Name not disclosed 
(oral) 
RaPharma C5 SM 
Zilucoplan extended 
release 
RaPharma C5 Peptide 
CP010 
Complement 
Pharma/Alexion 
C6 Ab 
  
 
 
 
Abbreviations (for diseases see Table 2): Ab, antibody; AP, alternative pathway; ASO, antisense 
oligonucleotide; RNAi, ribonucleic acid interference; CP, classical pathway; LP, lectin pathway; FB, 
factor B; FD, factor D; FH, factor H; FI, factor I; MASP, mannose-associated serine protease 1; PNS, 
peripheral nervous system; CNS, central nervous system; MAC, membrane attack complex; FDA, The 
Food and Drug Administration; EMA, European Medicines Agency; SM, small molecule; IV, 
intravenous; SC, subcutaneous; IVT, intravitreal; Ph, phase; RoA, route of administration; SoC, 
standard of care; ULN, upper limit of normal; AQP4, Aquaporin-4. 
 
Table 3. Drugs in current clinical trial. Each line represents a clinical trial and these are shaded 
according to the phase of development. Only company-sponsored trials are indicated and completed 
trials are excluded. Red text indicates that a drug has already been approved for treatment of a 
different indication and is being trialled for a new purpose. For disease abbreviations refer to Table 
1. For modality and route of administration please refer to Table 2. HV; healthy volunteer. 
* Recently approved by FDA for NMOSD, June 2019 
 
 
Drug Phase 1 (or 1/2) Phase 2 Phase 3 
AAVCAGscd59 GA,  NCT03144999 
AAVCAGscd59 wAMD,  NCT03585556 
ABP 959 (eculizumab biosimilar) HV, ACTRN12616000509460 
Danicopan (ACH-4471) C3G/IC-MPGN, NCT03124368 (proof-of-mechanism) 
Danicopan C3G,  NCT03369236 
Danicopan C3G/IC-MPGN,  NCT03459443 
Danicopan PNH,  NCT03181633 
Danicopan PNH (combination, inadequate response to Eculizumab);  NCT03472885 
ACH-5228 HV 
ACH-5448 HV 
AMY-101 Gingivitis,  NCT03694444 (Ph 1/2) 
APL-2 PNH,  NCT03500549 
APL-2 PNH, NCT03531255 
APL-2 GA,  NCT03525600,  
APL-2 GA, NCT03525613 
APL-2 neovascular AMD,  NCT03465709 (Ph 1/2) 
APL-2 WAIHA, CAD,  NCT03226678 
APL-2 IgAN, LN, MN, C3GN, DDD,  NCT03453619 
APL-9 HV 
Avacopan AAV, NCT02994927 
Avacopan C3G, NCT03301467 
Avacopan HS,  NCT03852472 
Berinert Add-on to Standard of Care, refractory AMR, NCT03221842 
Cemdisiran IgAN,  NCT03841448 
Cinryze Donor pre-treatment in KT; NCT02435732 
Crovalimab (SKY59) PNH,  NCT03157635 (Ph1/2) 
Eculizumab gMG (pediatric), NCT03759366 
Eculizumab* Relapsing NMO extension study,  NCT02003144 
IFX-1 PG, NCT03971643 
IFX-1 HS,  NCT03487276 
IFX-1 AAV: GPA, MPA,  NCT03712345 (add on to SoC) 
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IFX-1 AAV: GPA, MPA,  NCT03895801 (steroid replacement) 
IONIS-FB-LRX AMD (GA),  NCT03815825 
IONIS-FB-LRX IgAN, NCT04014335 
LPN023 IgAN 
LPN023 C3G 
LNP023 PNH 
Mirococept Ischaemia-reperfusion injury associated with renal transplantation 
(Registry: ISRCTN49958194) 
Narsoplimab (OMS721) TMA, aHUS,  NCT03205995 
Narsoplimab IgAN,  NCT03608033 
Narsoplimab LN, MN, C3G,  NCT02682407 
Narsoplimab TMA, NCT02222545 
Nomacopan (Coversin) PNH,  NCT03588026 
Nomacopan PNH in patients resistant to eculizumab,  NCT03427060 
Nomacopan Long Term Safety and Efficacy in PNH & aHUS, NCT03829449 
Nomacopan BP (Europe) 
Nomacopan Ph 1/2, atopic keratoconjunctivitis (AK) 
Pozelimab PNH 
Ravulizumab aHUS (Adults and Adolescents, treatment naive),  NCT02949128 
Ravulizumab aHUS (Children and Adolescents),   NCT03131219 
Ravulizumab gMG,  NCT03920293 
Ravulizumab PNH (Children and Adolescents), NCT03406507 
Ruconest DGF after KT, NCT03791476 
Sutimlimab BP, CAD, wAIHA, NCT02502903 
Sutimlimab CagD (Cardinal study),  NCT03347396 
Sutimlimab CagD (Cadenza study), NCT03347422 
Tesidolumab PNH, NCT02534909   
Zilucoplan PNH extension study,  NCT03225287 
Zilucoplan gMG,  NCT03315130 
Zilucoplan IMNM, NCT04025632 
Zilucoplan Renal disorders 
Zimura STGD1,  NCT03364153 
Zimura GA,  NCT02686658  
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